{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Aadi Bioscience, Inc.
Aadi Bioscience Hits New 52-Week High of $4.13, Up 134.48%
Aadi Bioscience, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low and showcasing strong one-year performance compared to the S&P 500. Despite its market capitalization and notable stock movement, the company faces financial challenges, including operating losses and a negative return on equity.
Aadi Bioscience Hits New 52-Week High of $3.94, Up 115.52%
Aadi Bioscience, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low and showcasing a strong one-year performance. With a market capitalization of USD 144 million, the company operates in a competitive sector, despite currently facing financial challenges.
Aadi Bioscience Stock Forms Golden Cross, Signaling Bullish Breakout Ahead
Aadi Bioscience, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators show a predominantly bullish sentiment, despite a challenging year-to-date performance. The stock has outperformed the S&P 500 over the past year, suggesting renewed interest as it navigates the biotech landscape.
Is Aadi Bioscience, Inc. technically bullish or bearish?
As of September 11, 2025, Aadi Bioscience, Inc. shows a neutral trend with mixed technical signals, having underperformed the S&P 500 year-to-date but outperformed it over the past month, suggesting a cautious investment approach.
Is Aadi Bioscience, Inc. overvalued or undervalued?
As of May 8, 2025, Aadi Bioscience, Inc. is considered an attractive investment due to its undervalued status with a P/E ratio of 3, a Price to Book Value of 0.40, and a high ROCE of 648.45%, despite a year-to-date stock decline of 38.19%, indicating significant growth potential compared to its peers.
Is Aadi Bioscience, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is neutral with mixed indicators, showing mildly bullish signals from the weekly MACD and KST, but mildly bearish sentiment from daily moving averages and Bollinger Bands, resulting in no clear direction from the RSI.
What does Aadi Bioscience, Inc. do?
Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing treatments for ocular diseases and diabetic complications. As of March 2025, it reported net sales of $7 million and a net profit of $73 million, with a market cap of $94.69 million.
How big is Aadi Bioscience, Inc.?
As of Jun 18, Aadi Bioscience, Inc. has a market capitalization of 94.69 million and net sales of 27.77 million with a net profit of 27.62 million over the latest four quarters. As of Dec 24, shareholder's funds are 52.48 million and total assets are 70.71 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
